EBITDA Margin % is calculated as EBITDA divided by its Revenue. Formycon AG's EBITDA for the
six
months ended in Dec. 2025 was €40.28 Mil. Formycon AG's Revenue for the
six
months ended in Dec. 2025 was €35.48 Mil. Therefore, Formycon AG's EBITDA margin for the quarter that ended in Dec. 2025 was 113.54%.
Formycon AG (FRA:FYB) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Formycon AG EBITDA Margin % Related Terms
Formycon AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Formycon AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:FYB vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Formycon AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formycon AG EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Formycon AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Formycon AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formycon AG (FRA:FYB) has a EBITDA Margin % of 113.54% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Formycon AG and its competitors. According to the industry distribution chart, Formycon AG ranks #321 out of 944 companies in the Biotechnology industry, placing it in the top 34%.
Is Formycon AG's EBITDA Margin % too high?
Formycon AG's current EBITDA Margin % is 113.54%. Based on the distribution chart, Formycon AG ranks #321 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Formycon AG has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formycon AG ranks #321 out of 944 companies for EBITDA Margin %. This puts Formycon AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Formycon AG and its competitors. Formycon AG's current EBITDA Margin % is 113.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Based on GuruFocus' analysis, Formycon AG (FRA:FYB) is currently considered Possible Value Trap. The stock's GF Value™ is €35.48, compared to a current price of €18.56 — trading 47.7% below its estimated fair value. The current EBITDA Margin % is 113.54%. Formycon AG's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Formycon AG (FRA:FYB), the current EBITDA Margin % is 113.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formycon AG (FRA:FYB) Overvalued in 2026?
Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued.
The current stock price of €18.56 is trading 47.7% below its estimated GF Value™ of €35.48.
GuruFocus considers Formycon AG to be Possible Value Trap.
Key valuation signals for FRA:FYB:
EBITDA Margin %: 113.54%
GF Value™: €35.48 vs. price of €18.56 (47.7% below fair value)
No single metric tells the full story. See the FRA:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
65GF Score
Get the complete analysis for FRA:FYB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FYB has been successfully added to your 
